Bempedoic acid for the treatment of dyslipidemia
Posted at2021-03-26

Cardiovascular disease (CVD) is the leading cause of death worldwide and one key factor associated with the increased CVD risk is dyslipidemia. Statin therapy remains the first-line treatment to manage dyslipidemia, yet many patients do not achieve optimal low-density lipoprotein-cholesterol (LDL-C) levels even after taking moderate- or high-intensity statins,therefore, non-statin therapy is often needed additionally.

Bempedoic acid is a prodrug that, once activated, decreases LDL-C levels by the inhibition of adenosine triphosphate citrate lyase in the liver. Five clinical trials have demonstrated the safety and efficacy of bempedoic acid and the bempedoic acid/ezetimibe combination in lowering LDL-C in patients with atherosclerotic CVD and heterozygous familial hypercholesterolemia and also in high-risk primary prevention, and statin-intolerant patients. Bempedoic acid has been demonstrated to lower LDL-C levels by 15–25% in clinical trials and up to 38% when combined with ezetimibe.

In 2020, the FDA approved bempedoic acid.

Furthermore, the combination of bempedoic acid with ezetimibe is FDA approved for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic CVD who require additional LDL-C lowering after maximally tolerated statin therapy. The ongoing CLEAR OUTCOMES trial aims to evaluate whether bempedoic acid can reduce cardiovascular events in patients with statin intolerance and results will be available in the next 3 years. This outcomes trial will be pivotal for determining the role of bempedoic acid in the non-statin lipid-lowering armamentarium.

Glad to share that we have achieved the research on the API and intermediates of Bempedoic Acid:

①API:Bempedoic acid/ETC-1002

CAS No.738606-46-7


Appearance:White solid

In stock,available for experiment only.



CAS No.123469-92-1


Appearance:Colorless oil

Single impurity:<0.5%

Commercially manufacturing.



③Intermediate:2,2,14,14-tetramethyl-8-oxopentadecanedioic acid diethyl ester

CAS No.738606-43-4


Appearance:Light yellow Liquid

This intermediate is difficult to make but we successfully made and sold kg+ scale.


Other intermediates of Bempedoic acid are available too!


Speranza Chemical-We focus on pharma intermediates research and enlarge production from 1kg ~ Tons.


Any interest, welcome to contact for more information!

Copyright 2016 Speranza Chemical Co., Ltd. All rights reserved.